Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)

被引：0
|
作者：
Fontana, A.
Bocci, G.
Galli, L.
Derosa, L.
Minuti, G.
D'Arcangelo, M.
Santini, D.
Landi, L.
Bursi, S.
Falcone, A.
机构：
[1] ASL6, Livorno, Italy
[2] Univ Pisa, ITT, Pisa, Italy
[3] ASL6, ITT, Livorno, Italy
[4] Univ Campus Bio Med, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel
    Beardsley, E. K.
    Saad, F.
    Eigl, B.
    Venner, P.
    Hotte, S.
    Winquist, E.
    Ko, Y. J.
    Sridhar, S. S.
    Chi, K. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] Impact of intermittent (I) first-line docetaxel (D)-based chemotherapy on quality of life (QL) of patients (pts) with castration-resistant prostate cancer (CRPC): Results of a phase II randomized trial
    Caffo, Orazio
    Sava, Teodoro
    Basso, Umberto
    Buti, Sebastiano
    Lo Re, Giovanni
    Sacco, Cosimo
    Lodde, Michele
    Facchini, Gaetano
    Zustovich, Fable
    Perin, Alessandra
    Russo, Lucianna
    Veccia, Antonello
    Galligioni, Enzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [33] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [34] Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel
    Arsov, Christian
    Winter, Christian
    Rabenalt, Robert
    Albers, Peter
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (06) : 762 - 771
  • [35] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    T M Beer
    D C Smith
    A Hussain
    M Alonso
    J Wang
    M Giurescu
    K Roth
    Y Wang
    British Journal of Cancer, 2012, 107 : 808 - 813
  • [36] Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Roth, K.
    Wang, Y.
    BRITISH JOURNAL OF CANCER, 2012, 107 (05) : 808 - 813
  • [37] Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients
    Caffo, Orazio
    Lo Re, Giovanni
    Sava, Teodoro
    Buti, Sebastiano
    Sacco, Cosimo
    Basso, Umberto
    Zustovich, Fable
    Lodde, Michele
    Perin, Alessandra
    Facchini, Gaetano
    Veccia, Antonello
    Maines, Francesca
    Barile, Carmen
    Fratino, Lucia
    Gernone, Angela
    De Vivo, Rocco
    Pappagallo, Giovanni L.
    Galligioni, Enzo
    FUTURE ONCOLOGY, 2015, 11 (06) : 965 - 973
  • [38] TREATMENT EFFECT AND COSTS OF THE COMPLETE THERAPEUTIC PATHWAY IN PATIENTS WITH FIRST-LINE CASTRATION-RESISTANT PROSTATE CANCER WITH EITHER FIRST-LINE DOCETAXEL OR ABIRATERONE ACETATE PLUS PREDNISONE
    Holleman, M. S.
    Santi, I
    Huygens, S.
    Aben, K. K. H.
    Van den Bergh, A. C. M.
    Bergman, A. M.
    van den Eertwegh, A. J. M.
    Kuppen, M. C. P.
    Lavalaye, J.
    Mehra, N. M.
    van Moorselaar, R. J. A.
    Van Oort, I. M.
    Somford, D. M.
    Westgeest, H. M.
    Gerritsen, W. R.
    Uyl-De Groot, C. A.
    VALUE IN HEALTH, 2022, 25 (01) : S266 - S267
  • [39] Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer
    Chi, K. N.
    Hotte, S. J.
    Yu, E.
    Tu, D.
    Eigl, B.
    Tannock, I.
    Saad, F.
    North, S.
    Powers, J.
    Eisenhauer, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [40] Overcoming docetaxel resistance in advanced castration-resistant prostate cancer (CRPC): A phase I/II trial of the combination of temsirolimus and docetaxel
    Duran, Ignacio
    Montagut, Clara
    Calvo, Emiliano
    Galtes, Susana
    Navarrete, Alicia
    Rodriguez-Pascual, Jesus
    Hidalgo, Manuel
    Francisco Rodriguez-Moreno, Juan
    Cubillo, Antonio
    Garcia, Antonia
    Sanchez, Lorena
    Barbas, Coral
    Viqueira, Andrea
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
12345